New Delhi (Business Emerge/Asia): Novo Nordisk has begun commercial sales of Ozempic in India as part of its plan to expand access to treatments for type 2 diabetes and weight-related health risks. The company confirmed that the product is now available in multiple dose strengths, with its lowest weekly dose priced at USD 24.35.
The launch took place on Friday, marking Novo Nordisk’s formal entry into a market where the prevalence of type 2 diabetes and rising body-weight-related concerns have created strong demand for medical interventions. The injectable will be supplied in a pen device that delivers 0.25 mg, 0.5 mg or 1 mg doses in weekly administration.
Company disclosures showed that the monthly pricing has been fixed at 8,800 rupees for the 0.25 mg option, 10,170 rupees for the 0.5 mg option and 11,175 rupees for the 1 mg option. Each device will contain four individual doses intended for a one-month treatment cycle.
Ozempic received approval from the United States Food and Drug Administration in 2017 as a once-weekly injectable for type 2 diabetes. The medicine has since grown into a widely used therapy worldwide, with many patients using it for weight-management outcomes. The company stated that the product supports glycemic control and also reduces the likelihood of cardiovascular and kidney-related complications for eligible patients.
Novo Nordisk’s India leadership said the drug has shown meaningful weight-reduction outcomes in individuals with type 2 diabetes. The company indicated that patients in clinical settings have experienced weight changes that extend beyond blood-sugar management, which has contributed to its rising global adoption.
India ranks second globally in the number of people living with type 2 diabetes, following China. The country is also witnessing a steady rise in obesity levels across age groups, creating a rapidly expanding consumer base for metabolic and weight-related treatments. Pharmaceutical manufacturers view India as a key long-term market because of its large population and increasing healthcare spending.
Industry assessments suggest that the global demand for medicines in the weight-management category is set to increase sharply. Forecasts project that the segment could reach annual revenues of approximately USD 150 billion by the end of this decade as more countries adopt such therapies and as treatment awareness rises.
Novo Nordisk had previously planned for an India launch within this year to establish a presence before local manufacturers bring semaglutide-based alternatives to market. The active ingredient in Ozempic, semaglutide, is expected to go off-patent in March 2026, creating an opportunity for domestic companies to introduce lower-cost variants.
The availability of Ozempic is likely to influence prescription patterns in India’s diabetes-care ecosystem, particularly among endocrinologists and general practitioners managing long-term metabolic conditions. The launch also places Novo Nordisk in direct competition with other global and domestic developers that are preparing similar treatments.
Analysts expect that the introduction of a globally recognised therapy may increase patient interest in medically supervised weight-management options. Healthcare providers may also explore broader adoption as new clinical evidence, patient outcomes and pricing structures emerge over time.
With the product now accessible in India, the next phase will likely involve monitoring distribution, supply consistency and patient uptake across major metropolitan and regional locations. The company is expected to expand availability further as demand stabilises and healthcare practitioners integrate the therapy into long-term care plans.
